Medical Device

Viveve Medical (NASDAQ: VIVE) a medical technology company focused on women’s intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform into the stress urinary incontinence (SUI) market, the results from a recently completed 12-month pilot study and plans for two clinical registration studies to further assess the safety and efficacy of …

Viveve Medical (NASDAQ: VIVE) a medical technology company focused on women’s intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform into the stress urinary incontinence (SUI) market, the results from a recently completed 12-month pilot study and plans for two clinical registration studies to further assess the safety and efficacy of the Viveve System in the treatment of mild-to-moderate SUI.
As quoted in the press release:

“Our practice has treated women with vaginal laxity using Viveve’s CMRF technology for more than five years. For SUI, the combined cooling and deep tissue capability of CMRF effectively targets the connective tissue that plays a critical role in the structural integrity of the vagina and the urinary system. In the pilot study, we found that SUI symptoms were significantly improved, providing strong support for the planned clinical registration studies and the potential to represent a major advance in the non-invasive treatment of SUI,” said Dr. Allan.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20101.38-389.63
TSXV691.17-21.32
DOW31490.07-1164.52
S&P 5003923.68-165.17
NASD11418.15-566.37
ASX7112.50+19.50

COMMODITIES

Commodities
Gold1816.41+1.83
Silver21.34-0.28
Copper4.15-0.03
Palladium1998.00-47.00
Platinum931.00-20.00
Oil108.06-1.53
Heating Oil3.56-0.01
Natural Gas8.14-0.23

DOWNLOAD FREE REPORTS

×